Objective-The purpose of this study was to investigate the influence of cGMP-dependent kinase I (cGKI) on platelet production. Approach and Results-We used hematology analyser to measure platelet counts in conventional cGKI-null mutants (cGKI L1/L1 ), gene-targeted cGKIα/β rescue mice (referred to as cGKI-smooth muscle [SM]) in which cGKI expression is specifically restored only in SM, platelet factor 4-Cre tg/+ ; cGKI L2/L2 mice in which the cGKI protein was specifically deleted in the megakaryocyte/platelet lineage and cGKI-deficient bone marrow-chimeras. Thrombocytosis was detected in cGKI L1/L1 and in cGKI-SM. In contrast, neither platelet factor 4-Cre tg/+ ; cGKI L2/L2 nor cGKI-deficient bone marrowchimeras displayed a thrombocytosis phenotype, indicating that the high platelet count in cGKI L1/L1 and cGKI-SM mutants is attributable to loss of an extrinsic signal rather than reflecting an intrinsic defect in megakaryopoiesis. Cytometric analyses further showed that stimulation of bone marrow-derived wild-type megakaryocytes in vitro using serum preparations obtained from cGKI-SM mutants strongly accelerated megakaryopoiesis, suggesting that the high platelet count develops in response to serum factors. Indeed, using ELISA assay, we found elevated levels of interleukin-6, a known stimulator of thrombopoiesis, in cGKI-SM mutant serum, whereas interleukin-6 levels were unaltered in platelet factor 4-Cre tg/+ ; cGKI L2/L2 mice and cGKI-deficient bone marrow-chimeras. Accordingly, antibody-mediated blockade of interleukin-6 normalized platelet counts in cGKI-SM mice.
A high platelet count has the potential to be associated with thrombosis and paradoxical bleeding. Clinically significant thrombocytosis is characterized by a high platelet count resulting from a multitude of pathogeneses, including infections, chronic inflammation, malignancies or iron deficiency and myeloproliferative disorders. 1 Megakaryopoiesis and thrombopoiesis are tightly regulated by serum factors, such as thrombopoietin 2 which acts in concert with several cytokines (eg, interleukin-3, interleukin-6, and interleukin-11) to maintain differentiation, proliferation, maturation of megakaryocytes, and the release of platelets. 3, 4 Megakaryopoiesis involves megakaryocyte lineage commitment from pluripotent hematopoietic stem and progenitor cells, proliferation of megakaryocyte progenitors, complex maturation steps of megakaryocytes and, finally, the release of platelets into the blood. 3, 4 Hematopoietic stem and progenitor cells give rise to a common megakaryocyte/erythroid progenitor. 5 Megakaryocyte/erythroid progenitors further differentiate into highly proliferative potential colony forming unit-megakaryocytes, burst-forming unit-megakaryocytes, and colony forming unit-megakaryocytes with an increasing lineage specification. [6] [7] [8] [9] [10] Colony formation units-megakaryocytes eventually differentiate into megakaryoblasts, which are characterized by a reduced proliferation capacity and >2 N DNA ploidy. 10 DNA polyploidization results from nuclear endomitosis and is accompanied by extensive morphological and cytoskeletal changes involving an increase in cell size, the development of a complex membranous network known as the demarcation membrane system, and the synthesis of platelet-specific proteins and granules. 11 Together, these changes give rise to the platelet production machinery of mature megakaryocytes that release thrombocytes into the bone marrow (BM)-sinusoid vessels via long cytoplasmic processes, termed proplatelets. 12 Fundamental functions of cAMP/cGMP signaling in mature platelets have been recognized for many years [13] [14] [15] ; however, the role of cAMP or cGMP in the maturation of megakaryocytes and the production of platelets in vivo are much less known. Recent in vitro findings indicate that platelet release from fetal liver cells-derived megakaryocytes is enhanced by high cGMP, but blocked by high cAMP levels in response to prostaglandin I 2 or agonists that directly activate adenylyl cyclase. 16 As in many other cell types, the rate of cGMP production through soluble guanylyl cyclase activity and its degradation via cGMP-hydrolyzing phospodiesterases (PDEs) determine the amplitude, duration, and spatiotemporal distribution of an intraplatelet cGMP signal. 17 Of the 3 known platelet PDE isoforms, 2 isoforms, PDE-2 and PDE-3, may maintain an intensive cross-talk between nitric oxide (NO)/soluble guanylyl cyclase/cGMP and prostaglandin I 2 /adenylyl cyclase/ cAMP because these PDEs limit, with different affinities for their substrates and with different catalytic rates, the levels of both cyclic nucleotides, producing either inactive 5´-AMP or 5´-GMP. 18 Most effects of high intraplatelet cGMP are directly mediated by cGMP-dependent protein kinase type I (cGKI), which is presumably the major effector of NO/cGMP in many cells. 13, 14 Interestingly, mature platelets express only the cGKIβ isozyme, whereas in numerous other cell types, such as hippocampal neurons and vascular or visceral smooth muscle (SM) cells, 2 cGKI isoforms, cGKIα and cGKIβ, act downstream of NO and cGMP. 19 In platelets, NO/cGMP signaling via cGKIβ efficiently opposes most agonist-induced and Ca 2+ -dependent activation/aggregation steps. 13, 20, 21 However, the effect of cGKI on megakaryopoiesis and platelet biogenesis in vivo is not completely known.
To study the role of cGMP/cGKI signaling in megakaryopoiesis and platelet production in vivo, we took advantage of several established or recently generated transgenic mouse lines. 22 Interestingly, we detected high platelet counts in conventional cGKI-null mutants (cGKI L1/L1 ) and in adult cGKI-SM mice with cGKI expression specifically restored in SM, but not in other cell types, 22 whereas cGKI-null megakaryocytes developed normally under in vitro conditions. Moreover, neither platelet factor 4 (Pf4)-Cre tg/+ ; cGKI L2/L2 mice, 23 in which cGKI was specifically ablated only in the megakaryocyte/platelet lineage, nor cGKI-deficient BM chimeras developed a similar thrombocytosis phenotype, indicating that the loss of cGKI in megakaryocytes and all radiosensitive hematopoietic cells does not contribute to thrombocytosis in cGKI-SM mutants. Our further investigations revealed that elevated interleukin-6 serum levels, which are known to enhance platelet production, are a plausible cause for thrombopoiesis in cGKI-SM mice because antibody-mediated inhibition of interleukin-6 normalized platelet counts in cGKI-SM but not in wild-type (WT) littermates. Taken together, our results suggest that the presence of cGKI in hematopoietic cells is not required for normal thrombopoiesis but the deficiency of cGKI in nonhematopoietic cells affects interleukin-6 turnover or production, resulting in a high platelet count in vivo. Our findings reveal a novel function of cGKI in thrombopoiesis and suggest that dysfunction of cGMP/cGKI signaling in nonhematopoietic cells leads to high platelet counts, which may lead to hemostatic problems.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Thrombocytosis in cGKI-Deficient Mice
We first confirmed that the cGKI protein was highly expressed in BM megakaryocytes and platelets ( Figure 1A and 1B). 22 To examine potential functions of cGKI in platelet biogenesis, we next measured total platelet counts in conventional cGKI-null mice. Platelet counts in 3-week-old cGKI L1/L1 mice were significantly higher as compared with WT littermates ( Figure 1C ). As reported previously, ≈50% of the cGKI L1/ L1 null mutants die before 5 to 6 weeks of age 24 ; hence, to investigate the role of cGKI in thrombopoiesis in adult mice, and to bypass severe SM dysfunctions caused by the cGKI Figure 1 . Thrombocytosis in cGMPdependent protein kinase type I (cGKI)deficient mice. A, Representative immunohistochemical staining of cGKI (blue) in wild-type (WT; left) and cGKIsmooth muscle (SM; right) bone marrow. Arrows indicate stained megakaryocytes. Scale bars, 50 µm. B, Representative immunoblot for the cGKI protein in platelet lysates collected from WT and cGKI-SM mice. β-Actin was used to demonstrate equal loading of the gels. C, Platelet counts in peripheral blood from male WT littermates and cGKI L1/L1 mutants (n=7 WT littermates; n=4 cGKI L1/L1 mutants; SV129 background). Platelet counts (D) and mean platelet volume (E) in peripheral blood of female WT and cGKI-SM littermates (n=11 WT and n=10 cGKI-SM mice; SV129 background). All error bars represent SEM.
inactivation, we used a mouse line with restored expression of either the cGKIα or the cGKIβ isozyme specifically in SM, but not in other cell types. 22 The so-called cGKIα/β SM rescue mice (cGKI-SM) showed a prolonged life expectancy and normal vascular and visceral SM functions, as compared with cGKI L1/L1 null mutants. 22 As expected, cGKI-SM mice displayed a similar thrombocytosis phenotype as cGKI L1/ L1 mutants ( Figure 1D ), excluding the potential contribution of age or SM defects to elevated platelet counts. In addition, platelet volumes were larger in cGKI-SM mice as compared with WT littermates ( Figure 1E ), indicating an essential function of cGMP/cGKI for megakaryopoiesis and thrombopoiesis in vivo.
Megakaryocyte Polyploidization and Megakaryocyte Counts Are Increased in the BM of cGKI-SM Mice
Because the initial analyses of different cGKI mutants suggested that the thrombocytosis phenotype could be related to a primary defect in the developing megakaryocyte/platelet lineage, we examined platelet life span and megakaryopoiesis in the peripheral blood and BM, respectively. Interestingly, the platelet life span in cGKI-SM mice was reduced rather than increased (Figure 2A ), suggesting that the extent of platelet overproduction might be underestimated in vivo. It is possible that an enhanced platelet adhesion and aggregation in response to agonists in cGKI-deficient animals at least in part contributes to the faster clearance of platelets from the circulation observed here. 13 The slightly shorter life span of cGKI-SM platelets ( Figure 2A ) together with the overproduction of platelets ( Figure 1D ) is likely to increase the proportion of new-born platelets in the whole platelet population in cGKI-SM mice, which explains the increase in platelet volume in these mutants ( Figure 1E ), given that newly formed platelets are bigger than mature platelets. Next, colony formation units-megakaryocyte assays using mononuclear BM cells derived from cGKI-SM mice and WT littermates demonstrated that megakaryocyte progenitor counts in both genotypes were comparable ( Figure 2B ). However, histological and flow cytometric analyses revealed that BM megakaryocyte counts and the percentage of BM megakaryocytes with a DNA content >8 N were significantly elevated in cGKI-SM mice ( Figure 2C-2E ). These results indicate an enhanced megakaryopoiesis in cGKI-SM mice.
Megakaryocyte cGKI Is Not Required for Megakaryopoiesis and Thrombopoiesis In Vitro and Under Physiological Conditions In Vivo
To examine the role of cGKI for megakaryocyte maturation in more detail, we used BM-or fetal liver-derived cells, and differentiated them into megakaryocytes in vitro. Given that the number of megakaryocyte progenitors was not affected by cGKI ablation in the BM ( Figure 2B ), megakaryocyte proliferation from BM-derived megakaryocyte progenitors in vitro was similar for cGKI-null and WT cells ( Figure 3A) . In contrast to the higher polyploidization of cGKI-deficient megakaryocytes in vivo, the polyploidization rate of cultivated BM-derived cGKI null and WT megakaryocytes was not different ( Figure 3B ). Next, we studied proplatelet formation as an important functional property of megakaryocytes in fetal liver cells-derived megakaryocytes. Our data showed that the extent of proplatelet formation was not affected by cGKIdeficiency ( Figure 3C ). To further investigate the function of cGKI for proplatelet fragmentation, which is the final stage of thrombopoiesis, we applied our previously described in vitro model, which enables us to monitor proplatelet fragmentation events triggered by 10 μmol/L sphingosine 1-phosphate (S1P) using time-lapse video differential interference contrast microscopy. 12 Our findings show that a similar extent of S1Ptriggered proplatelet fragmentation was observed in cGKIdeficient megakaryocytes and WT megakaryocytes ( Figure 3D , Figure IA , and Movie I in the online-only Data Supplement), respectively, suggesting that cGKI is not involved in the regulation of S1P-induced proplatelet fragmentation.
Together, the in vitro experiments did not support our initial hypothesis that cGKI plays an intrinsic role in thrombocytosis. As a final test of whether cGKI signaling plays an intrinsic (autonomous) role in megakaryopoiesis in vivo, we generated gene-targeted mice with a megakaryocyte-and plateletspecific cGKI ablation. Mice carrying floxed cGKI alleles (cGKI L2/L2 ) were crossed to Pf4-Cre transgenic mice, which express Cre recombinase under control of the megakaryocytespecific promoter Pf4. 23 In conditional knockout animals (Pf4-Cre tg/+ ; cGKI L2/L2 ), the cGKI protein was specifically ablated in platelets ( Figure 3E ), whereas other cardiovascular cell types that express cGKI were unaffected by the conditional ablation ( Figure 3E ). Although cGKI was efficiently inactivated in megakaryocyte/platelets, our analysis showed that loss of cGKI in this lineage did not change platelet counts and mean platelet volume in the peripheral blood, confirming that the abnormal platelet counts in the peripheral blood of cGKI L1/L1 and cGKI-SM mice did not result from an intrinsic dysfunction of cGKI ( Figure 3F and 3G) . Notably, platelet counts in Pf4-Cre +/+ ; cGKI L2/L2 mice were slightly, but significantly higher than in WT littermates for cGKIL1/L1 and cGKI-SM ( Figure 1C and 1D, Figure 3F ). This may result from different backgrounds of mouse lines because Pf4-Cre +/+ ; cGKI L2/L2 mice were bred on an SV129/B6 background, whereas cGKIL1/L1 and cGKI-SM mice were on an SV129 background. Together with the in vitro findings, these data clearly rule out an intrinsic function of cGKI in platelet biogenesis. 
Thrombocytosis of cGKI-SM Mutant Mice Does Not Result From Defects in the Hematopoietic System
Then we asked whether hematopoietic cells other than megakaryocytes contribute to thrombocytosis in cGKI-SM mice. To address this, we generated BM chimeras by transferring BM cells from WT littermates or conventional cGKI-null mice into lethally irradiated WT recipient mice. After 11 weeks, we observed a successful reconstitution of the recipient's hematopoietic system with donor BM as indicated by anti-Ly9.1 and peripheral blood cytometric analyses ( Figure IB in the online-only Data Supplement). Interestingly, cGKI-null BM chimeras showed normal platelet counts and normal platelet size ( Figure 4A and 4B) . Therefore, cGKI-deficiency in radiosensitive hematopoietic cells does not cause the thrombocytosis phenotype of cGKI L1/L1 and cGKI-SM mutant mice.
Thrombocytosis in Gene-Targeted cGKI-SM Mutants Is Triggered by a Serum Factor
It is known that factors produced and secreted by nonhematopoietic cells modulate megakaryocyte and platelet biogenesis in vivo in a paracrine/endocrine manner. 3, 4 To test this hypothesis, we analyzed BM-derived megakaryocytes cultured in serum-free medium supplemented with serum collected from either cGKI-SM or WT littermates. The cGKI-SM serum significantly increased the number of megakaryocytes in WT BM cell preparations in vitro ( Figure 4C) . Moreover, the stimulation of megakaryocytes using serum from cGKI-SM mice significantly elevated the percentage of megakaryocytes with a DNA content of ≥4 N ( Figure 4D ), reminiscent of our observations in BM of cGKI-SM mice ( Figure 2E ). Thus, cGKI dysfunction in nonhematopoietic cells may cause a disturbed megakaryocyte/platelet homeostasis via factors present in the blood serum of cGKI mutant mice.
Enhanced Interleukin-6 Serum Levels Contribute to Thrombocytosis in cGKI-SM Mice
To clarify which serum factor enhances platelet biogenesis in cGKI-SM mice, we determined the serum levels of the key cytokines for megakaryocytopoiesis and platelet biogenesis in vivo, including thrombopoietin and interleukin-6. 3, 4 Serum thrombopoietin levels in cGKI-SM mice were significantly reduced as compared with WT littermates (Figure 5A ), whereas thrombopoietin levels were unaltered in Pf4-Cre tg/+ ; cGKI L2/L2 mice or cGKI-deficient BM chimeras as compared with their respective controls ( Figure 5B and 5C) . Given that free thrombopoietin levels inversely correlate with platelet counts, lower serum thrombopoietin levels are consistent with the higher number of platelets in cGKI-SM mice ( Figure  1D ). 2 As previously reported, 25 interleukin-6 serum levels were significantly elevated in cGKI-SM mice, whereas in cGKI-deficient BM chimeras and Pf4-Cre tg/+ ; cGKI L2/L2 mice, which did not develop a similar thrombocytosis phenotype ( Figures 3F and 4A , respectively), interleukin-6 was detected at control levels ( Figure 5D -5F). However, basal interleukin-6 levels were higher in BM chimeras than in nontransplanted animals most likely resulting from a chronic graft-versushost immunoreactivity response after the allogeneic BM transplantations. 26 Notably, interleukin-6 concentrations did not differ between serum and plasma preparations from WT mice, excluding an effect of the platelet releasate on our above observations (data not shown).
It is well known that interleukin-6 enhances thrombopoiesis both in vitro and in vivo [27] [28] [29] ; therefore, increased interleukin-6 serum levels could be a reason for the thrombocytosis phenotype in cGKI-SM mice. To prove this, we tested whether antagonizing interleukin-6 reduces the platelet counts of cGKI mutant mice. cGKI-SM mice were treated with an interleukin-6 neutralizing antibody, as previously reported, to block Figure 4 . Serum factors contribute to enhanced thrombopoiesis. A, Platelet counts in peripheral blood from wild-type (WT) and cGMP-dependent protein kinase type I (cGKI) L1/L1 bone marrow (BM) chimeras. Donor BM cells from cGKI L1/L1 and WT female littermates (SV129 background) were transferred into WT female recipient mice (B6 background). The counts were performed 11 weeks after the transplantation (n=11 for WT BM chimeras and n=13 for cGKI L1/L1 BM chimeras). B, Mean platelet volume in peripheral blood from WT and cGKI L1/L1 BM chimeras. Donor BM cells from cGKI L1/L1 and WT female littermates (SV129 background) were transferred into WT female recipient mice (B6 background). The measurements were performed 8 weeks after the transplantation (n=12 for WT BM chimeras and n=15 for cGKI L1/L1 BM chimeras). biological function of interleukin-6 in vivo. 30, 31 Our targeted therapy indeed normalized the platelet counts in cGKI-SM mice, whereas the approach had no effects on platelet counts in WT littermates ( Figure 5G ). Together, these data suggest that elevated interleukin-6 serum levels enhance megakaryopoiesis and platelet production in cGKI-SM mice in vivo.
Interleukin-6 Signaling Increases the Volume of Megakaryocytes, But Has No Effect on Megakaryocyte Positioning, Motility, Proplatelet Formation, or Proplatelet Shedding In Vivo
Despite these well-known effects of interleukin-6 on megakaryopoiesis, [27] [28] [29] the effect of interleukin-6 on dynamic megakaryocyte behavior, for example, positioning, motility, proplatelet formation, and shedding, has been insufficiently addressed in vivo. To test whether these dynamic megakaryocyte functions are directly affected by high interleukin-6 levels, we performed multiphoton intravital microscopy. Using multiphoton intravital microscopy, we visualized megakaryocytes in calvarian BM from CD41-yellow fluorescent protein mice, 32 in which megakaryocytes specifically express the yellow fluorescent protein under control of the endogenous CD41 gene promoter. To analyze the interaction and localization of megakaryocytes in relation to the blood stream, we labeled blood plasma by intravenous injection of 2 MDa tetramethylrhodamine isothiocyanate-dextran. 12 In line with previous findings, 28 we observed that the 3-dimensional volume of megakaryocytes from interleukin-6 treated mice (1.7 μg/mouse every 8 hours for 3 days) was much larger as compared with control mice ( Figure 6A) ; however, interleukin-6 did not change the motility and positioning of megakaryocytes ( Figure 6B and 6C, Movie II in the online-only Data Supplement), suggesting that interleukin-6 has no effect on megakaryocyte migration. We previously discovered that proplatelets polarize into BM sinusoid vessels in vivo, which is essential for efficient platelet production. 12 To examine the effect of interleukin-6 on the polarization of proplatelets, we next studied the distribution of proplatelets and their relationships to BM sinusoid vessels. Using multiphoton intravital microscopy, we detected that megakaryocytes from interleukin-6 treated and untreated mice protruded proplatelets into BM sinusoidal vessels ( Figure 6D and 6E and Movie III in the online-only Data Supplement). Importantly, there was no difference between the treated and untreated control groups, indicating that interleukin-6 has no effect on polarization of proplatelets in vivo. Finally, the potential role of interleukin-6 for proplatelet fragmentation and shedding was assessed. We observed proplatelet shedding events in interleukin-6 treated mice as frequently as in untreated control mice ( Figure 6F , Figure II , and Movie IV in the online-only Data Supplement), ruling out any effect of interleukin-6 on proplatelet shedding. Taken together, neither migration nor polarization or fragmentation of proplatelets is disturbed by high interleukin-6 levels; however, interleukin-6 enlarges megakaryocyte cell bodies in vivo, suggesting an effect on megakaryocyte maturation.
Discussion
The cGMP-dependent protein kinase type I is an important downstream target of NO. The pleiotropic effects of NO in the Figure 5 . Higher interleukin-6 (IL-6) serum levels result in thrombocytosis in cGMP-dependent protein kinase type I (cGKI)-smooth muscle (SM) mice. A-C, Serum thrombopoietin (Tpo) levels in different cGKI mutant mice and bone marrow (BM) chimeras (n=6 for wild-type [WT] nontransplanted littermates; n=6 for cGKI-SM; n=8 for platelet factor 4 (Pf4)-Cre +/+ ; cGKI L2/L2 ; n=6 for Pf4-Cre tg/+ ; cGKI L2/L2 ; n=6 for WT BM chimeras and n=6 for cGKI-null BM chimeras). D-F, IL-6 serum levels in different cGKI mutant mice and BM chimeras (n=13 for WT nontransplanted littermates; n=9 for cGKI-SM; n=8 for Pf4-Cre +/+ ; cGKI L2/L2 ; n=6 for Pf4-Cre tg/+ ; cGKI L2/L2 ; n=10 for WT BM chimeras and n=12 for cGKI L1/L1 BM chimeras). G, Treatment of mice with IL-6 neutralizing antibody. Baseline levels of platelet counts were assessed 7 days before administration of IL-6 antibody or its corresponding IgG control. Platelet counts were measured again 2 days after the last administration of IL-6 neutralizing antibody or IgG control (n=5 female mice per group; SV129 background). Black bars, WT; white bars, cGKI-SM. All error bars represent SEM.
cardiovascular system include modulating vessel tone, blood homeostasis, megakaryocyte maturation, platelet formation, and platelet function. [33] [34] [35] [36] [37] [38] [39] Pharmacological studies have shown that NO can induce apoptosis in megakaryocytes in vitro; however, these inhibitory effects of NO on megakaryocyte growth were not dependent on cGMP but were mediated via proapoptotic factors, such as Bax, Bcl-2, and peroxynitrite formation. 35, 36 Battinelli et al reported that NO increased production of platelet-like particles from a human megakaryocyte cell line and that cytokine-inducible nitric oxide synthase -/mice have reduced platelet counts, 34 suggesting that NO is directly involved in thrombopoiesis in vivo. Using a conditional approach, we targeted cGKI specifically in the megakaryocyte/ platelet lineage and confirmed that megakaryocyte cGKI does not intrinsically affect megakaryocyte maturation or platelet production. In line with our present findings, Begonja et al 16 have recently shown that the cGMP/cGKI pathway has no effect on megakaryocyte development in vitro and does not affect megakaryocyte proliferation or polyploidization. These authors further showed that a pharmacological stimulation of the cGMP pathway enhanced release of platelet-like particles from fetal liver cells-derived megakaryocytes, 16 suggesting that the cGMP/cGKI pathway might play a role in platelet biogenesis. However, here we did not observe any effects of endogenous cGKI on platelet production under physiological conditions in different cGKI mutant mouse lines. Several reasons are likely to explain this discrepancy between our present observation and the previous report by Begonja et al 16 : first, pharmacological overstimulation of cGMP/cGKI pathway might indeed enhance platelet formation in vitro as suggested by Begonja et al 16 ; however, intrinsic megakaryocyte cGMP/ cGKI signaling should not be overstimulated under physiological conditions in vivo. Thus, we conclude from our in vivo data that the physiological activity of megakaryocyte cGMP/cGKI pathway is not essential for thrombopoiesis. Nevertheless, overstimulation of cGMP/cGKI pathway might enhance platelet formation under pathophysiological conditions. Second, potential roles of cGKI in thrombopoiesis might be compensated by other pathways on cGKI inactivation in cGKI-deficient mice. Third, 8-pCPT-cGMP and BAY41-2272, which were used in the previous report, might activate other molecules downstream of cGMP besides cGKI pathway.
Although cGKI is not intrinsically required for thrombopoiesis in vivo, our results showed that the deficiency of cGKI in nonhematopoietic systems disturbed the homeostasis of platelet biogenesis in vivo. Elevated interleukin-6 serum levels were detected in cGKI-SM mice, but not in cGKI-deficient BM chimeras or Pf4-Cre tg/+ ; cGKI L2/L2 animals. In line with our observations, Lutz et al 25 reported that the interleukin-6 serum levels were significantly increased in cGKI-SM mice probably by a mechanism involving cGMP/cGKI in liver, but not in skeletal muscles, spleen, or white adipose tissue. 25 However, very recently it was shown that an inhibition of RhoA via cGMP/ cGKI efficiently prevents the production of inflammatory factors, such as interleukin-6 in white adipocytes. 40 The exact source and the cause of elevated interleukin-6 serum levels in cGKI mutant mice still remain to be identified in future studies.
Interleukin-6 is an essential cytokine in the regulation of megakaryopoiesis and thrombopoiesis. Previous research showed that interleukin-6 can increase megakaryocyte size and DNA ploidy in in vitro liquid culture. 41 Ishibashiet et al reported that interleukin-6 increased platelet counts and megakaryocyte size in a dose-dependent fashion. 28 Other studies confirmed that platelet production and megakaryocyte numbers are elevated by increased interleukin-6 in mice. 29 In humans, high interleukin-6 serum levels are 1 of the major causes for thrombopoiesis. 1 In line with these previous reports, 1, [27] [28] [29] 41 an anti-interleukin-6 therapy normalized platelet counts in cGKI-SM mice ( Figure 5G ). This is a very important finding because with age cGKI-SM mice suffer from gastrointestinal bleedings, which might be related to severe hematological changes, including a high platelet count. 42 Despite these well-known effects of interleukin-6 on megakaryopoiesis, the role of interleukin-6 on in vivo functions of megakaryocytes, such as motility, positioning, and dynamic processes of platelet release, has not been investigated in detail. Using multiphoton intravital microscopy to visualize megakaryocytes within BM in vivo, we found that interleukin-6 increases the megakaryocyte volume in vivo ( Figure  6A ). 28 However, the migration of megakaryocytes and their localization in the BM were not altered by interleukin-6. In agreement with our findings, it has been demonstrated that fibroblast growth factor 4 and stromal cell-derived factor-1 rather than megakaryocyte-active cytokines, including thrombopoietin interleukin-6, or interleukin-11, play a predominant role for the localization of megakaryocyte progenitors to the vascular niche, eventually promoting thrombopoiesis. 43 Our previous studies reveal that the chemotactic S1P gradient controls polarization of proplatelets into BM sinusoid vessels via the S1P/S1pr1 signaling pathway. 12 Once megakaryocytes extend proplatelets into the blood stream, shear stress and S1P promote proplatelet shedding into the circulation. 12, 44 Here, we report that interleukin-6 affected neither polarization of proplatelets into BM sinusoid vessels nor proplatelet fragmentation or shedding. Thus, elevated interleukin-6 serum levels may increase platelet production and megakaryopoiesis by boosting megakaryocyte proliferation and polyploidization, but not by controlling the processes that guide platelet formation.
Taken together, our findings indicate that cGKI is not intrinsically required for homeostasis of platelet biogenesis, but the deficiency of cGKI in nonhematopoietic systems leads to a nonautonomous thrombocytosis phenotype, which is most likely driven by chronically elevated interleukin-6 serum levels.
These results provide new insights into the cGMP/cGKI pathway and its role for the pathophysiology of thrombocytosis and its causes.
